Pfizer Investigational Site
New Haven, Connecticut, 06511, United States
NCT Number: NCT00774605
To evaluate the absorption, safety, and tolerability of a varenicline solution and a varenicline patch applied to the skin.
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
New Haven, Connecticut, 06511, United States
Additional Study Purpose Details: Evaluation of the pharmacokinetic profile of a varenicline solution and a varenicline patch applied to the skin
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
Time frame: 8 days
Time frame: 8 days
Pfizer
Industry
A Phase 1, Open-Label, Nonrandomized, Single Dose Study To Characterize The Pharmacokinetics Of A Varenicline (CP-526,555) Transdermal Solution And A Varenicline Transdermal Delivery System Applied To The Skin Of Adult Smokers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05049174
Behavior, Cardiovascular Diseases
Drammen, Akershus, Norway
View Trial DetailsNCT05224154
Acceptability of Health Care, Behavior
Glassboro, New Jersey, United States
View Trial DetailsNCT06943287
Behavior, Health Behavior
Iowa City, Iowa, United States
View Trial DetailsNCT04505371
Behavior, Blood-Borne Infections
Seattle, Washington, United States
View Trial Details